94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1589243
This article is part of the Research TopicThe Role of Metabolic Reprogramming in Tumor TherapyView all 11 articles
Metabolic Reprogramming and Immune Microenvironment Characteristics in Laryngeal Carcinoma: Advances in Immunotherapy
Provisionally accepted- 1Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
- 2Department of Otolaryngology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
- 3Department of Otolaryngology Head and Neck Surgery, Affiliated Huai’an Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China
- 4Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Nantong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Laryngeal squamous cell carcinoma (LSCC) is a prevalent malignancy with high mortality and recurrence rates, necessitating novel therapeutic strategies. Recent research highlights the pivotal role of metabolic reprogramming and immune microenvironment alterations in LSCC pathogenesis, providing promising avenues for targeted therapy. This review summarizes the metabolic characteristics of LSCC, including glycolysis, lipid metabolism, and amino acid biosynthesis, and their implications for tumor progression and therapeutic resistance. Additionally, this review further describes the tumor microenvironment's immunosuppressive landscape, including immune checkpoint regulation, tumor-associated macrophages, and T-cell dysfunction. The integration of metabolic and immune-targeted strategies represents a promising frontier in LSCC treatment, warranting further investigation.
Keywords: Laryngeal squamous cell carcinoma, metabolic reprogramming, Tumor Microenvironment, immune checkpoint inhibitors, Glycolysis, precision medicine, Immunotherapy
Received: 07 Mar 2025; Accepted: 08 Apr 2025.
Copyright: © 2025 Ma, Mao, Fei, Ni, Zhang and Ni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Haosheng Ni, Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Nantong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.